When Your Vijoice Prescription Isn't Available

If you're dealing with PIK3CA-Related Overgrowth Spectrum (PROS) and can't fill your Vijoice (Alpelisib) 50 mg prescription, the situation can feel alarming. Vijoice is the only FDA-approved medication for PROS, and when you can't access it—whether because of insurance delays, specialty pharmacy issues, or other barriers—you need to know what other options exist.

Let's look at what Vijoice does, how it works, and what alternatives your doctor might consider if you're facing a gap in access.

What Is Vijoice 50 Mg 28 Day?

Vijoice is the brand name for Alpelisib, manufactured by Novartis. It received FDA accelerated approval in April 2022 as the first and only treatment specifically approved for PROS—a spectrum of rare conditions caused by somatic mutations in the PIK3CA gene.

PROS conditions include a range of overgrowth disorders that can affect blood vessels, lymphatic tissue, fat, bone, and other structures. These conditions are present from birth, though symptoms can appear and progress over time. The 50 mg tablet is the standard starting dose for pediatric patients (ages 2 to 17), taken once daily with food.

For a complete overview of the medication, see our article on what is Vijoice: uses, dosage, and what you need to know.

How Does Vijoice Work?

Vijoice works by selectively inhibiting the PI3K-alpha isoform—a protein that is overactive in people with PIK3CA mutations. When the PIK3CA gene is mutated, it causes cells to grow and divide abnormally, leading to the tissue overgrowth that defines PROS.

By blocking PI3K-alpha, Vijoice helps reduce this abnormal cell proliferation. In clinical studies, 27% of patients achieved a measurable radiological response (more than 20% reduction in target lesion volume) at 24 weeks, and 60% of responders maintained their response for 12 months or longer.

For more details, check out our explainer on how Vijoice works: mechanism of action explained.

Alternative Treatments for PROS

While Vijoice is the only FDA-approved drug for PROS, there are other treatment approaches that have been used—some for years before Vijoice was approved. These are all decisions to make with your specialist, not on your own.

1. Sirolimus (Rapamune)

What it is: Sirolimus is an mTOR inhibitor that has been used off-label to treat PROS for several years, particularly before Vijoice received FDA approval.

How it works: The PI3K pathway that Vijoice targets feeds into the mTOR pathway downstream. By blocking mTOR, Sirolimus can slow abnormal cell growth, though it acts at a different point in the signaling cascade than Vijoice.

Key considerations:

• Available as a generic medication, making it significantly more affordable than Vijoice
• Has a longer track record of use in PROS patients
• Requires regular blood level monitoring
• Side effects can include mouth sores, increased infection risk, elevated cholesterol, and decreased blood cell counts
• Not FDA-approved specifically for PROS—used off-label

Sirolimus remains a reasonable option for patients who cannot access Vijoice or who have not responded adequately to it.

2. Miransertib (Investigational)

What it is: Miransertib is an AKT inhibitor currently being studied in clinical trials for PIK3CA-related overgrowth disorders.

How it works: AKT is a protein that sits downstream of PI3K in the same signaling pathway. By inhibiting AKT, Miransertib aims to reduce the abnormal growth driven by PIK3CA mutations through a different molecular target.

Key considerations:

• Still in clinical trials and not yet FDA-approved
• May be available through clinical trial enrollment
• Ask your specialist if any active trials are enrolling
• Represents a promising future option for patients with PROS

3. Surgical and Procedural Interventions

What they include: Debulking surgery, sclerotherapy, laser therapy, and other procedural approaches to manage localized overgrowth.

Key considerations:

• Often used in combination with systemic therapy, not as a replacement
• Can provide significant relief for specific lesions or functional impairments
• Risk of regrowth means procedures may need to be repeated
• Best managed by multidisciplinary teams at vascular anomalies centers

4. Supportive and Symptomatic Care

Beyond targeted drug therapy and surgery, PROS management often involves:

• Compression garments for lymphatic and vascular overgrowth
• Physical and occupational therapy to maintain function and mobility
• Pain management as needed
• Regular imaging and monitoring to track disease progression

These supportive measures don't replace Vijoice or other targeted therapy but are an important part of overall PROS care.

What to Do If You Can't Fill Your Vijoice Prescription Right Now

1. Contact your prescriber immediately — Let them know about the access issue so they can explore alternatives or escalate the pharmacy situation.
2. Check Medfinder — Search for Vijoice availability near you before assuming it's unavailable everywhere.
3. Call Novartis patient support at 1-877-577-7756 — They can help troubleshoot insurance, prior authorization, and pharmacy issues.
4. Ask about Sirolimus as a bridge — If the delay will be more than a few days, your doctor may consider Sirolimus as a temporary alternative.
5. Don't stop treatment without talking to your doctor — Suddenly stopping PROS treatment can lead to symptom progression. Always consult your specialist before making changes.

Final Thoughts

Vijoice 50 Mg 28 Day is the gold standard for treating severe PROS, but it's not the only tool available. If you're facing an access gap, options like Sirolimus and surgical interventions have helped PROS patients for years. The most important thing is to stay in close contact with your specialist and not go without treatment unnecessarily.

For more on finding Vijoice, read our guides on how to find Vijoice in stock near you and how to save money on Vijoice.